Cover Story

Although control of blood glucose remains a primary goal in the treatment of type 2 diabetes (T2D), substantial effort is also directed toward reducing the development of diabetes-associated vascular complications, for example by reducing blood pressure. Glucagon-like peptide-1 (GLP-1) is a gut hormone with pleiotropic effects that, among other actions, also controls heart rate (HR). The data available so far suggest that GLP-1 may control HR indirectly, through modulation of autonomic nervous system activity, as well as directly, through control of pacemaker activity via the atrial GLP-1 receptor (GLP-1R). To elucidate the relative importance of and inter-dependence of these pathways, Baggio, Ussher et al. have now studied the regulation of HR in control and Glp1rCM-/- mice treated with the GLP-1R agonists lixisenatide or liraglutide. The importance of the autonomic nervous system was examined in mice co-administered propranolol or atropine. Their findings reveal temporally distinct contributions from both the sympathetic nervous system and cardiac GLP-1Rs in the HR response to GLP-1R agonism in mice in vivo. In contrast, the isolated perfused mouse heart or dissected atrial preparations did not exhibit a direct chronotropic response to GLP-1R agonists ex vivo. Hence, the atrial GLP-1R mediates a HR response to GLP-1R agonism in the context of the intact mouse heart in vivo, but is not sufficient for transduction of a heart- autonomous chronotropic response ex vivo.

Full Text
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.



Patricia Brubaker, Andrew Biancolin
University of Toronto, ON, Canada
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at www.sciencedirect.com/journal/molecular-metabolism
Conferences & Events
January
26 − 30
2020
Keystone Sym­posium:
Cancer Epigenetics

Keystone, USA
January
27 − 30
2020
Keystone Sym­posium: Diabetes - Glucose Control and Beyond
Santa Fe, USA
January
27 − 30
2020
Keystone Sym­posium:
Islet Biology

Santa Fe, USA
February
23 − 27
2020
Keystone Sym­posium:
Obesity and NAFLD

Banff, Canada
February
24 − 27
2020
2nd Nuclear Receptors Conference
Nassau, Bahamas
March
1 − 5
2020
Keystone Sym­posium:
Biology of Exercise

Keystone, USA
March
10 − 11
2020
Dutch Translational Metabolism Conference
Lunteren, Netherlands
March
8 − 12
2020
Keystone Sym­posium:
Tumor Metabolism

Banff, Canada
March
22 − 26
2020
Keystone Sym­posium:
Gut-Systemic Perspective of Metabolic Disease

Santa Fe, USA
April
3 − 7
2020
Keystone Sym­posium:
Metabolism and Immunity

Keystone, USA
April
22 − 24
2020
Helmholtz:
Pseudokinases and Tribbles

Munich, Germany
Media Coverage
Supported by